Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C26H40N4O9S |
Molecular Weight | 584.682 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CS(=O)(=O)N[C@@H](CCCCN)C(=O)NC[C@H](CC1(CCCC1)C(=O)N[C@@H](CC2=CC=C(O)C=C2)C(O)=O)C(O)=O
InChI
InChIKey=LPUDGHQMOAHMMF-JBACZVJFSA-N
InChI=1S/C26H40N4O9S/c1-40(38,39)30-20(6-2-5-13-27)22(32)28-16-18(23(33)34)15-26(11-3-4-12-26)25(37)29-21(24(35)36)14-17-7-9-19(31)10-8-17/h7-10,18,20-21,30-31H,2-6,11-16,27H2,1H3,(H,28,32)(H,29,37)(H,33,34)(H,35,36)/t18-,20-,21-/m0/s1
Molecular Formula | C26H40N4O9S |
Molecular Weight | 584.682 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9797801
After a 4-week placebo run-in period, 124 patients with a mean blood pressure of 162/102 mm Hg were randomized in a double-blind parallel-group design to 1 of 5 treatments, given once daily for 10 days: 50 mg, 100 mg, or 200 mg sampatrilat
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 16:23:09 GMT 2023
by
admin
on
Sat Dec 16 16:23:09 GMT 2023
|
Record UNII |
V7O29949TG
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C247
Created by
admin on Sat Dec 16 16:23:09 GMT 2023 , Edited by admin on Sat Dec 16 16:23:09 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m9759
Created by
admin on Sat Dec 16 16:23:09 GMT 2023 , Edited by admin on Sat Dec 16 16:23:09 GMT 2023
|
PRIMARY | Merck Index | ||
|
100000084070
Created by
admin on Sat Dec 16 16:23:09 GMT 2023 , Edited by admin on Sat Dec 16 16:23:09 GMT 2023
|
PRIMARY | |||
|
SUB10438MIG
Created by
admin on Sat Dec 16 16:23:09 GMT 2023 , Edited by admin on Sat Dec 16 16:23:09 GMT 2023
|
PRIMARY | |||
|
129981-36-8
Created by
admin on Sat Dec 16 16:23:09 GMT 2023 , Edited by admin on Sat Dec 16 16:23:09 GMT 2023
|
PRIMARY | |||
|
6324648
Created by
admin on Sat Dec 16 16:23:09 GMT 2023 , Edited by admin on Sat Dec 16 16:23:09 GMT 2023
|
PRIMARY | |||
|
C132269
Created by
admin on Sat Dec 16 16:23:09 GMT 2023 , Edited by admin on Sat Dec 16 16:23:09 GMT 2023
|
PRIMARY | |||
|
V7O29949TG
Created by
admin on Sat Dec 16 16:23:09 GMT 2023 , Edited by admin on Sat Dec 16 16:23:09 GMT 2023
|
PRIMARY | |||
|
CHEMBL42583
Created by
admin on Sat Dec 16 16:23:09 GMT 2023 , Edited by admin on Sat Dec 16 16:23:09 GMT 2023
|
PRIMARY | |||
|
7451
Created by
admin on Sat Dec 16 16:23:09 GMT 2023 , Edited by admin on Sat Dec 16 16:23:09 GMT 2023
|
PRIMARY | |||
|
DTXSID6057877
Created by
admin on Sat Dec 16 16:23:09 GMT 2023 , Edited by admin on Sat Dec 16 16:23:09 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
||
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|